Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database

BACKGROUND AND OBJECTIVE: Golimumab is a fully human anti-tumor necrosis factor monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This study estimated rates of prespecified outcomes in patients with RA, PsA or AS...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Drug Investig
Autors principals: Ziyadeh, Najat J., Geldhof, Anja, Noël, Wim, Otero-Lobato, Marijo, Esslinger, Suzan, Chakravarty, Soumya D., Wang, Yiting, Seeger, John D.
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2020
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7595963/
https://ncbi.nlm.nih.gov/pubmed/32779120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40261-020-00959-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars